Clinical Trial

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Study acronym: wAMD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Protocol Amendment History 4 changes
notable Trial sites reduced: 119 -> 113 locations 2026-07-07
notable Trial sites reduced: 125 -> 119 locations 2026-06-27
notable Trial sites reduced: 129 -> 125 locations 2026-05-05
notable Trial sites reduced: 140 -> 129 locations 2026-04-03
Trial Details
NCT Number NCT06683742
Lead Sponsor EyePoint Pharmaceuticals, Inc.
Conditions Wet Age Related Macular Degeneration, wAMD
Enrollment 400 participants
Start Date 2024-11-27
Primary Completion 2026-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-04